Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2701817rdf:typepubmed:Citationlld:pubmed
pubmed-article:2701817lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:2701817lifeskim:mentionsumls-concept:C0005841lld:lifeskim
pubmed-article:2701817lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:2701817lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:2701817lifeskim:mentionsumls-concept:C1518988lld:lifeskim
pubmed-article:2701817pubmed:issue10lld:pubmed
pubmed-article:2701817pubmed:dateCreated1990-10-17lld:pubmed
pubmed-article:2701817pubmed:abstractTextCarcinomatous tumors usually have a rather slow proliferation rate. However, this process is sensibly accelerated as soon as immunodepressive phenomena occur. Blood transfusions may result in the appearance of a considerable mass of alloantigens and in simultaneous immunomodulation. On the basis of a series of 469 patients, we are able to realize that the intra-and postoperative administration of blood during the curative resection of colorectal cancers produced a poor prognosis. We also followed up subjects who had had chemotherapy via the portal system for one week but no blood transfusion. The prognosis was definitely better in these patients, and proved to be 2 to 3 times as favorable as for patients receiving blood transfusions without chemotherapy. The various results are thoroughly analyzed, the primary aim being the study of the effects of intraoperative portal chemotherapy. This leads to advocating the restriction of blood transfusions, and the use of autotransfusion or hemodilution if required.lld:pubmed
pubmed-article:2701817pubmed:languagefrelld:pubmed
pubmed-article:2701817pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2701817pubmed:citationSubsetIMlld:pubmed
pubmed-article:2701817pubmed:statusMEDLINElld:pubmed
pubmed-article:2701817pubmed:issn0001-4001lld:pubmed
pubmed-article:2701817pubmed:authorpubmed-author:MetzgerUUlld:pubmed
pubmed-article:2701817pubmed:authorpubmed-author:HarderFFlld:pubmed
pubmed-article:2701817pubmed:authorpubmed-author:LafferUUlld:pubmed
pubmed-article:2701817pubmed:authorpubmed-author:BerresMMlld:pubmed
pubmed-article:2701817pubmed:authorpubmed-author:JäggiPPlld:pubmed
pubmed-article:2701817pubmed:issnTypePrintlld:pubmed
pubmed-article:2701817pubmed:volume115lld:pubmed
pubmed-article:2701817pubmed:ownerNLMlld:pubmed
pubmed-article:2701817pubmed:authorsCompleteYlld:pubmed
pubmed-article:2701817pubmed:pagination759-65; discussion 765-6lld:pubmed
pubmed-article:2701817pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:meshHeadingpubmed-meshheading:2701817-...lld:pubmed
pubmed-article:2701817pubmed:year1989lld:pubmed
pubmed-article:2701817pubmed:articleTitle[Blood transfusion, short perioperative intraportal chemotherapy and recurrence of colorectal cancer].lld:pubmed
pubmed-article:2701817pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2701817pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2701817pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:2701817pubmed:publicationTypeRandomized Controlled Triallld:pubmed